MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.
Exploring the companies and themes that make up this emerging and exciting new sector
Numinus Announces Closing of $40-Million Bought Deal Financing
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
New research provides evidence that a single dose of psilocybin can boost brain connections
Scientists in Denmark believe the psychedelic substance psilocybin might produce rapid and lasting antidepressant effects in part because it enhances neuroplasticity in the brain.
Red Light Holland Successfully Completes Sale and Import of iMicrodose Psychedelic Truffles into Canada Under a Health Canada Approved Psilocybin Import Permit
Red Light Holland imports psilocybin truffles into Canada from its Netherlands supply source.
D.C. Psychedelics Decriminalization Initiative Officially Takes Effect
A wide range of psychedelics such as psilocybin and ayahuasca are now officially the lowest local law enforcement in the nation’s capital as of Monday.
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
MINDCURE's new COO, Tarik Lebbadi, recently led an international division of Johnson & Johnson.
Will Court Challenges Lead To Psychedelics Legalization?
A Seattle doctor is suing the DEA for blocking access to psilocybin. Could this be the quickest road to psychedelic drug legalization?
Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering
Numinus announces a CAD$30 million bought deal financing with units priced at CAD$1.25.
Whole-brain simulations hint at the neurobiological mechanisms underlying psychedelic-induced entropy
Scientists have used advanced computer simulations to better understand the neurobiological mechanisms underlying the psychedelic experience.
Psychedelic drug users tend to have better overall physical health than non-users, study finds
The use of psychedelic substances is associated with better physical health, according to preliminary research published in the Journal of Psychopharmacology.
Psychedelic Drugs And The Placebo Effect
Part of the benefit from psychedelic medicine may actually be a Placebo Effect. Find out why that is actually a GOOD thing.
Lifetime psychedelic use may reduce likelihood of hypertension
Lifetime classic psychedelic use, particularly tryptamines, may be linked to lower odds for hypertension in the previous year, according to data published in Hypertension.